Amphotericin B (AmB) with deoxycholate (Fungizone) and AmB incorporated into mixed micelles (AmB-mixMs) composed of egg lecithin with glycocholate, deoxycholate, or taurocholate were compared as treatments for murine infections. For mice infected with Candida albicans, treatment consisted of a single intravenous injection; for mice infected with Cryptococcus neoformans, treatment consisted of two intravenous injections. The maximal tolerated doses of AmB as Fungizone were 1.25 mg/kg of body weight in mice with candidiasis and 2.5 mg/kg of body weight in mice with cryptococcosis. The AmB-mixMs were nontoxic to mice at doses of 80 and 100 mg/kg of body weight and were therapeutically more active than the maximal tolerated dose of Fungizone in both models of infection. However, when Fungizone or AmB-mixMs were administered at equivalent doses ofAmB, AmB-mixMs were more active in treating murine candidiasis, whereas Fungizone was more active in treating murine cryptococcosis.
Amphotericin B (AmB) formulated with deoxycholate and sodium phosphate is used clinically as Fungizone. It is highly effective in the treatment of systemic fungal infections, but its usefulness is limited by its toxicity to patients (10) . The problem is further aggravated in immunocompromised patients, in whom opportunistic fungal infections caused by Cryptococcus neoformans and various species of Candida may be life-threatening (30) .
In experimental studies in animals, the therapeutic index of AmB has been improved by incorporating it into several types of lipid-based formulations such as multilamellar lipid vesicles composed of saturated phospholipids (22) or small unilamellar vesicles composed of egg lecithin and cholesterol (1, 14) or by complexing AmB to open lipid structures composed of saturated phosphatidylcholine (9) or cholesteryl ester (18) . The preparation and standardization of some of these formulations are associated with a range of technical and commercial problems (32) which may make long-term use difficult. While some of these formulations have undergone successful clinical trials in humans (2), treatment failures have been reported (24) . Moreover, the safety of the long-term use of synthetic saturated phospholipids in the clinical setting has not been determined. While progress in the development of rational approaches to the development of delivery systems is impressive (19, 21, 22, 28) , these efforts have been hampered because of the deficiency in our understanding of the molecular basis of the biological activities of formulations containing AmB. Therefore, a vehicle which retains optimal therapeutic properties and that can be used safely is still being sought.
In previous in vitro studies, we observed that mixed micelles prepared from unsaturated phosphatidylcholine (egg yolk lecithin) and bile salt (glycocholate) significantly decreased the toxicity of Fungizone for human erythrocytes and cultured L cell fibroblasts, while it retained potent activity against Candida albicans and C. neoformans (6) . In the present study, we prepared formulations of AmB with egg lecithin and glyco-cholate (Egam), deoxycholate (Edam), and taurocholate (Etam) that were nontoxic to mice up to doses as high as 100 mg/kg of body weight. Here we report a comparison of the therapeutic efficacies of these formulations and Fungizone in the treatment of murine models of candidiasis and cryptococcosis. In the accompanying report (5) we consider the molecular and cellular aspects of the therapeutic activities of these formulations.
(The results described here were presented in part at the 92nd General Meeting of the American Society for Microbiology, New Orleans, La., 26 to 30 May 1992 [7] lower ratios, taurocholate did not disperse in the egg lecithinchloroform mixture. To the dispersion of egg lecithin-bile salts in chloroform was added AmB in doses ranging between 0 and 15 mg per vial, and the mixtures were shaken by hand. The chloroform was evaporated in a stream of nitrogen gas at room temperature and was then desiccated for 24 to 48 h over anhydrous calcium chloride under reduced pressure.
To hydrate the samples, 0.2-ml portions of sterile distilled water were added to the desiccated film and the mixtures were carefully vortexed. This was followed by the addition of 1.3 ml of 5% glucose and vortexing for an additional 2 min. Since the final product was not sterilized, aseptic conditions were used at all steps. Formulations containing glycocholate were termed Egam, those with deoxycholate were termed Edam, and those with taurocholate were termed Etam. The composition and drug/lipid ratios of the various AmB-mixMs are given in Table  1 . The doses of all formulations were expressed in terms of AmB doses. The mice received the following doses of AmB (in milligrams per kilogram) in constant doses of egg lecithin and the bile salt that was assayed: 1.2, 2.5, 5.0, 10, 20, 40, 80, and 100. The effects of modulations of the AmB to egg lecithin ratio on the stability and biological activities of Egam and Edam are under investigation. All samples containing AmB were protected from light exposure during preparation, storage, and application.
Source and preparation of organisms for in vivo studies. 24 h after infection and consisted of a single intravenous injection; for mice infected with C. neoformans, treatment consisted of two intravenous injections: the first was given 48 h after infection and the second was given 24 h later. The formulations of AmB as Fungizone, Egam, Edam, or Etam were prepared in 5% glucose solutions, and 0.2-ml portions were injected into the dorsal tail veins of infected mice. Controls were treated with glucose, were given empty micelles of the type and dose corresponding to those administered with AmB, or were given deoxycholate in the dose corresponding to the dose given with Fungizone. No differences in the effects of treatment on the number of survivors and the load of infections of the three groups of controls were observed.
Evaluation of therapeutic regimens. A census of surviving animals in the various treatment groups was taken every day for 31 to 35 days postinfection.
In separate experiments on the day when all control mice were dead but all AmB-mixM-treated mice were still alive, the experiments were terminated and all mice were necropsied. Organs were aseptically removed, and groups of three kidneys or three brains were homogenized in 3 ml of sterile saline by using a hand-held tissue homogenizer. Serial 10-fold dilutions were plated onto Sabouraud dextrose agar. After incubation at 37°C for 48 h, the number of CFU in the kidneys of mice infected with C. albicans and the brains of those infected with C. neoformans were determined and compared with the number of yeasts in comparable organs of Fungizone-treated survivors.
Statistical analysis. Survival curves were calculated by the Kaplan-Meier method, and tests for differences in survival distributions were based on a generalized Wilcoxon test; data for load of infection in organs of infected mice were compared by analysis of variance and nonparametric tests (12) . Differences were considered significant if P was <0.05.
RESULTS
Evaluation of AmB-mixMs in treatment of murine candidiasis. Figure 1A illustrates the dose-response of AmB as Fungizone when it was used to treat mice infected with C. albicans. In summary, our data suggest that in our model of murine candidiasis, the optimal therapeutic dose of Egam is 20 mg/kg. At lower doses, sporadic deaths occurred, whereas there was no further improvement in the lowering of the load of infection at higher doses.
Evaluation of AmB-mixMs in treatment of murine cryptococcosis. Figure 2A illustrates the dose-response of AmB as Fungizone on the survival of mice infected with C. neoformans. Mice treated with 0.6 mg of Fungizone per kg had a death rate similar to that of control mice. Mice treated with 1.2 and 2.5 mg of Fungizone per kg showed an increasing survival rate that was dose dependent. An increase in the dose of AmB to 5.0 mg/kg resulted in immediate deaths of 20% of the treated animals, and the surviving mice died at a rate similar to those that received 2.5 mg of AmB per kg. Immediate deaths were observed in 60% of mice that received 7.5 mg of Fungizone per kg, with the remaining 40% surviving up to 22 days postinfection. On the basis of these results, a dose of 2.5 mg/kg was selected as the maximal tolerated dose of AmB as Fungizone. Improvement of antifungal activity by using lipid-based AmB formulations whose toxicities allow administration of higher drug doses than those achievable with Fungizone is a common feature of various delivery systems (9, 18, 20, 25 (1, 20, 25) , while others have found lipid-based formulations to be more effective (9, 12, 33) .
Several reports (1, 15, 18) show the comparable therapeutic activities of lipid-based formulations and Fungizone when used at equivalent doses in murine models of cryptococcosis; however, the AmB-lipid complex was less effective than Fungizone (9). Thus, our results resemble those obtained with the AmBlipid complex (9) in showing that at equivalent doses the same formulation may be therapeutically more potent than Fungizone in C. albicans-infected mice and less potent in C. neoformans-infected mice. It is noteworthy that when used at equivalent doses, AmB complexed to cholesteryl sulfate and Fungizone were similarly effective in treating murine cryptococcosis (18) but Fungizone was more effective in treating coccidioidomycosis (11) .
We considered two possible reasons for the differences in the relative therapeutic activities of Fungizone and Egam in our two models of infections. It has been reported that incorporation of AmB into multilamellar liposomes (17, 29) or complexation to the monolauryl ester of sucrose (8) or to cholesteryl sulfate (16) affects the antifungal activity of AmB in vitro. Thus, it could be hypothesized that, in comparison with Fungizone, incorporation of AmB into mixed micelles increases the in vivo activity of AmB against C. albicans and decreases its activity against C. neoformans.
Although this hypothesis is not compatible with our findings in vitro, that is, that the decreases in damage to fungal cells by AmB-mixMs were comparable when C. albicans cells or C. neoformans cells were assayed (5), it cannot be completely rejected. It is possible that our assay in vitro was not predictive of the in vivo situation or, alternatively, that lower antifungal activity was not important in one model but was decisive in another.
The second possible reason for the differences in the relative therapeutic efficacies of Fungizone and Egam is linked to our finding that Egam is more stable than Fungizone in the presence of serum lipoprotein (5) . It can be assumed that Egam stays in blood longer and is scavenged more effectively by cells of the reticuloendothelial system than the AmB which has dissociated from Fungizone. These differences may affect the pharmacokinetics and the distribution of AmB in the bloodstream in a way that is advantageous for the treatment of candidiasis but is disadvantageous for the treatment of cryptococcosis. Whatever the reason, the finding that the relative therapeutic potencies of Fungizone and AmB-mixMs depend on the model of infection being treated deserves further attention.
